Eligo Bioscience, a gene-editing company focused on addressing diseases driven by the expression of bacterial genes from the microbiome, has announced a successful $30 million Series B funding round, led by Sanofi Ventures.
Live biotherapeutic product (LBP) developer, 4D Pharma, says it is building a ‘strong body of evidence’ for its portfolio of bacterial strains in relation to cancer, asthma, and neurodegenerative diseases, while the company also calls its recent dual...
“There is a new kid on the block to rival E. Coli, CHO and yeast,” says Dyadic International as it collaborates to widen the use of its C1 expression tech.
Lonza has launched an updated version of its cell imaging technology, which it says has improved image capture and data transfer options, and enables researchers to monitor cells remotely.
Assuring anaerobic conditions in a fermenter design for aerobic organisms will be key in making Ondek’s Helicobacter pylori-based immunotherapy, says 3P Biopharmaceuticals.
The Novo Nordisk Foundation has awarded a DKK118m ($17m) grant to fund development of a fermentation pilot plant for cell line scale up experiments at the Technical University of Denmark.
Phages, peptides and live biotherapeutics could help combat antibiotic-resistant bacteria but don’t expect heavy R&D investment until people start dying from post-operative infection, says EpiBiome.
Evercyte has teamed up with VTU Technology to develop cell culture media free from animal derived products, which the firm says is now essential for biomanufacturers.
Industrial microorganism design firm Ginkgo Bioworks expects to cut six months off development timelines using mini-bioreactor technology supplied by Sartorius Stedim Biotech (SSB).
Dutch biotech company, Micreos, announced yesterday that it has secured €12 million in funding for the clinical development of its antibacterial lysin technology, Staphefekt.
Dispatches from the Cell Therapy Manufacturing & Gene Therapy Congress
A newly discovered virus which infects intestinal bacteria might be a cause of obesity, but could increasing interest in bacteriophages drive new personalised medicines and alternatives to antibiotics?
Increased regulatory expectation in the environmental monitoring of microbiological media has driven demand for prepared solutions, says Cherwell Laboratories as it completes a facility expansion.
OncoMed Pharmaceuticals announced last week that the US Patent and Trademark Office granted its first US patent for technology to identify mAbs (monoclonal antibodies).
Lonza has granted access to its potency boosting expression system to antibody developer Sorrento Therapeutics just days after a signing a similar deal with Pfizer.
In a rare move, the FDA has publically released Alexion Pharmaceuticals’ response to a Form 483 following inspection of its US site and the discovery of microbial contamination.
3M, the US-headquartered multinational, has launched a new range of bio filters which it says raise the benchmarks for flow-rate, organism reduction and efficiency across a range of applications.
RecipharmCobra Biologics has received an EU patent for a genetic modification tech that allows antibiotic resistance genes to be removed after insertion is complete.
Millipore has expanded its microbial detection offering with Milliflex Quantum which, it says, enables manufacturers to respond to contamination issues earlier in the drug and vaccine production process.
Glycos Biotechnologies has produced lactic acid in a pilot plant using its sustainable technique, successfully scaling up from a laboratory setting to provide an alternate source for the chiral synthon.
Detection of Mycoplasma contamination in biologics manufacture can be cut from up to 35 days to four hours using Millipore’s MilliPROBE, according to the company.
Cellexus Biosystems, the UK company that designs, manufactures and
sells disposable cell growth technology for the biopharmaceutical
industry, is extending the rental plan offered on its CellMaker
Lite2 single-use bioreactor in response...
Industrial microbiology expert bioMerieux has acquired Australian
firm BTF, strengthening its quality control (QC) and manufacturing
quality assurance (QA) offerings to the pharmaceutical industry.
US researchers have shown certain organic solvents can be used to
selectively extract therapeutic proteins from host bacteria,
avoiding the need for cell lysis and increasing product purity by a
factor of five.
A new laboratory method for distinguishing pathogens from harmless
relatives has been developed by scientists in the US. The
high-throughput technique will enable the quick identification of
pathogens, which could be used for bioterror...
